The 8 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 13.00, with a high estimate of 30.00 and a low estimate of 8.00. The median estimate represents a +13.94% increase from the last price of 11.41.
The current consensus among 10 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since June, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.47
Reporting Date Aug 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.